BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

The study of savolitinib is a single-arm, multi-center, open-label, Phase II registration study to evaluate the efficacy, safety and tolerability of savoli...

August 29, 2023 | News

Zhiyi Biotech Begins Phase 1 Trial of SK10 for Chemo-induced Diarrhea

SK10, the first Bacteroides fragilis-based live biotherapeutic product (LBP) obtained FDA IND approval, is also the first LBP of Next-generation probi...

August 28, 2023 | News

Agenus Focuses on Fast-Tracking BOT/BAL Program for Cancer

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources t...

August 24, 2023 | News

Oracle Joins White House CancerX Initiative to Aid in the Fight Against Cancer

Oracle has been recognized as a founding member of CancerX. The public-private partnership was formed to drive innovations that can help reduce deaths...

August 23, 2023 | News

Mammotome Unveils HydroMARK™ Plus: Innovative Breast Biopsy Site Marker

"I am excited for this innovative biopsy marker to come to market," said Radiologist Dr. Evita Singh, Director of Breast Imaging at Karmanos Cancer In...

August 22, 2023 | News

Verily and OneOncology Announce Collaboration to Advance Cancer Research

Verily, an Alphabet precision health technology company, and OneOncology, the national platform for independent oncology practices, have established a stra...

August 17, 2023 | News

First Patient Dosed in Phase III Prostate Cancer Imaging Study of TLX591-CDx in China

The Phase III Illuccix China study (ClinicalTrials.gov ID: NCT05847348) is a prospective, open-label, single-arm, multicenter study in Chinese...

August 11, 2023 | News

Clarity's theranostic prostate cancer trial advances to highest dose level

Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) ha...

August 11, 2023 | News

DualityBio, BioNTech Expand Partnership for Solid Tumor Antibody-Drug Conjugate

The agreement further builds upon the strategic collaboration the companies announced in April 2023. Under the terms of the agreements, DualityBio will re...

August 08, 2023 | News

Peter Mac launches BindiMaps to help patients and visitors with vision impairments

The newly-installed service functions like Google Maps, but has been specifically developed to work indoors with a 10 to 20 times higher accuracy than GPS ...

August 03, 2023 | News

AI Medical Service Inc. Signs Joint Research Agreement with Stanford Medicine

AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research...

July 28, 2023 | News

GC Genome Enables Prognosis Prediction and Targeted Treatment in Breast Cancer

''We can gain vital insights into patient prognosis and make informed decisions regarding the most effective treatment strategies through ctDNA CNA...

July 27, 2023 | News

HaemaLogiX, Peter MacCallum Cancer Centre Announce Myeloma CAR-T Trial Agreement

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's ...

July 26, 2023 | News

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging tr...

July 25, 2023 | News

Stay Connected